News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hutchison China MediTech (Chi-Med): Total Voting Rights



11/30/2016 12:20:17 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

HONG KONG, CHINA--(Marketwired - November 30, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)

AIM/Nasdaq: HCM

Total Voting Rights

London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share capital of Chi-Med consisted of 60,703,323 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 60,703,323 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

For illustrative purposes only, the 60,703,323 ordinary shares would be equivalent to 60,703,323 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 121,406,646 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries Christian Hogg, CEO +852 2121 8200 International Media Enquiries Anthony Carlisle, +44 7973 611 888 Citigate Dewe Rogerson anthony.carlisle@cdrconsultancy. (Mobile) co.uk U.S. Based Media Enquiries Brad Miles, +1 (917) 570 7340 BMC Communications (Mobile) bmiles@bmccommunications.com Susan Duffy, +1 (917) 499 8887 BMC Communications (Mobile) sduffy@bmccommunications.com Investor Relations Matt Beck, +1 (917) 415 1750 The Trout Group (Mobile) mbeck@troutgroup.com David Dible, +44 7967 566 919 Citigate Dewe Rogerson (Mobile) david.dible@citigatedr.co.uk Panmure Gordon (UK) Limited Richard Gray / +44 (20) 7886 2500 Andrew Potts


Contacts:
RNS
Customer
Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES